# BioNTech

> Biotechnology company from Germany

**Wikidata**: [Q30256699](https://www.wikidata.org/wiki/Q30256699)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/BioNTech)  
**Source**: https://4ort.xyz/entity/biontech

## Summary
BioNTech is a German biotechnology company known for developing the Pfizer–BioNTech COVID-19 vaccine in collaboration with Pfizer. Founded in 2008 and headquartered in Mainz, Germany, it operates as a public pharmaceutical company focused on innovative immunotherapies and mRNA-based treatments. The company gained global prominence for its rapid development of an effective mRNA vaccine against SARS-CoV-2.

## Key Facts
- Founded in 2008 in Mainz, Germany
- Operates as a public company in the pharmaceutical industry
- Notable for developing the Pfizer–BioNTech COVID-19 vaccine, an mRNA-based immunization against SARS-CoV-2
- Co-founded by Uğur Şahin and Özlem Türeci, both prominent German physicians and researchers
- Collaborated with Katalin Karikó, a Hungarian biochemist, whose research on mRNA was foundational to the vaccine development
- Also known by aliases: Biopharmaceutical New Technologies, Biontech, BioNTech SE, BioNTech AG, BNT, BNTX, BionTech
- Employs approximately 1,300 people
- Generated revenue of €108.6 million, €127.6 million, and €61.6 million in recent years (source: financials)
- Reported net losses of €-179.2 million, €-47.7 million, and €-86.0 million in corresponding periods
- Total assets reported at €797.6 million, €653.0 million, and €374.7 million
- Website: [https://biontech.de/](https://biontech.de/)
- Listed on Nasdaq, an American electronic stock exchange
- Sitelink count: 45

## FAQs
### What is BioNTech?
BioNTech is a German biotechnology company that specializes in developing immunotherapies and mRNA-based treatments. It is most widely recognized for co-developing the Pfizer–BioNTech COVID-19 vaccine with Pfizer.

### When was BioNTech founded?
BioNTech was founded in June 2008 in Mainz, Germany.

### Who are the founders of BioNTech?
The company was co-founded by Uğur Şahin and Özlem Türeci, both German physicians and scientists. Şahin is a German oncologist known for his work in cancer immunotherapy and vaccine development.

### What is the Pfizer–BioNTech COVID-19 vaccine?
It is an mRNA-based vaccine developed by BioNTech in cooperation with Pfizer to prevent infection by the SARS-CoV-2 virus, which causes COVID-19. It was one of the first effective vaccines to receive emergency authorization globally.

### What is the relationship between BioNTech and Pfizer?
BioNTech partnered with Pfizer to develop, test, and distribute the Pfizer–BioNTech COVID-19 vaccine. The collaboration leveraged BioNTech’s expertise in mRNA technology and Pfizer’s global manufacturing and distribution capabilities.

### Where is BioNTech located?
BioNTech is headquartered in Mainz, the capital of Rhineland-Palatinate, Germany.

### What is the significance of mRNA technology in BioNTech's work?
mRNA technology allows the body to produce an immune response by instructing cells to create a protein that triggers immunity. This approach was central to the rapid development of the Pfizer–BioNTech COVID-19 vaccine.

### Who else contributed to BioNTech's mRNA research?
Katalin Karikó, a Hungarian biochemist, conducted foundational research on modifying mRNA to reduce its immunogenicity, making it viable for therapeutic use. Her work was instrumental in the development of BioNTech's mRNA vaccines.

### Is BioNTech a public company?
Yes, BioNTech is a public company listed on Nasdaq, one of the largest electronic stock exchanges in the United States.

### What are BioNTech’s main business areas?
BioNTech focuses on developing individualized cancer immunotherapies, infectious disease vaccines, and protein replacement therapies using mRNA technology.

## Why It Matters
BioNTech became globally significant for its role in developing one of the first effective vaccines against the SARS-CoV-2 virus, which caused the worldwide COVID-19 pandemic. Its mRNA platform, developed over years of research, enabled the rapid creation of a vaccine that was crucial in curbing the pandemic. The company’s success has demonstrated the potential of mRNA technology in medicine, opening new pathways for treating cancer, infectious diseases, and rare genetic disorders. Its partnership with Pfizer also exemplifies how biotech innovation can scale globally through strategic alliances.

## Notable For
- Developing the first widely distributed mRNA-based vaccine for COVID-19
- Pioneering the use of mRNA technology in vaccines and immunotherapies
- Being one of the fastest companies to develop a vaccine during a global health crisis
- Founding by Uğur Şahin and Özlem Türeci, both internationally recognized scientists
- Collaboration with Katalin Karikó, whose foundational mRNA research enabled the vaccine’s success
- Being a publicly traded company on Nasdaq with global reach
- Generating significant revenue and assets during the pandemic, despite reporting net losses due to high R&D costs
- Operating as a leader in the pharmaceutical industry’s shift toward personalized medicine and mRNA-based treatments

## Body

### History
BioNTech was founded in June 2008 in Mainz, Germany, by Uğur Şahin and Özlem Türeci. The company was established with a focus on mRNA technology and immunotherapy, particularly for cancer treatment. Over the years, it developed a robust pipeline of mRNA-based treatments and vaccines, which positioned it to respond rapidly to the SARS-CoV-2 pandemic in 2020.

### Leadership and Key Figures
- **Uğur Şahin**: A German oncologist and co-founder of BioNTech, Şahin played a central role in developing the Pfizer–BioNTech COVID-19 vaccine. His expertise in cancer immunotherapy and mRNA technology was pivotal in the company’s success.
- **Özlem Türeci**: Co-founder and physician, Türeci has been instrumental in shaping BioNTech’s scientific direction and clinical development strategies.
- **Katalin Karikó**: Though not affiliated with BioNTech as an employee, Karikó’s research on modified mRNA was foundational to the development of BioNTech’s mRNA platform. Her work enabled the creation of stable and immunogenic mRNA molecules used in the vaccine.

### Products and Innovations
BioNTech is most notable for the **Pfizer–BioNTech COVID-19 vaccine**, an mRNA-based immunization developed in collaboration with Pfizer. This vaccine was one of the first to show high efficacy against the SARS-CoV-2 virus and was authorized for emergency use in multiple countries.

The company also focuses on:
- **Cancer immunotherapies** using individualized mRNA treatments
- **Infectious disease vaccines** beyond COVID-19
- **Protein replacement therapies** for rare diseases

### Business and Financials
BioNTech is a **public company** listed on **Nasdaq**, which has enabled it to raise capital for its research and global operations. Despite its success, the company reported **net losses** in recent years:
- Net profit: -€179.2 million, -€47.7 million, -€86.0 million
- Revenue: €108.6 million, €127.6 million, €61.6 million
- Total assets: €797.6 million, €653.0 million, €374.7 million
- Employees: ~1,300

### Affiliations and Collaborations
BioNTech has a strategic partnership with **Pfizer**, particularly for the development and distribution of the **Pfizer–BioNTech COVID-19 vaccine**. This collaboration combined BioNTech’s mRNA platform with Pfizer’s global infrastructure to deliver the vaccine at an unprecedented scale.

### Headquarters and Operations
The company is headquartered in **Mainz**, the capital of Rhineland-Palatinate, Germany. This location serves as the central hub for its research, development, and administrative operations.

### Industry Classification
BioNTech is classified as a **pharmaceutical company** operating within the **pharmaceutical industry**, which involves the development, production, and marketing of medications, including vaccines like the Pfizer–BioNTech COVID-19 vaccine.

### Technology and Innovation
BioNTech’s core innovation lies in its **mRNA technology platform**, which allows for rapid development of vaccines and immunotherapies. This technology was critical in the rapid response to the SARS-CoV-2 pandemic and continues to be the foundation of its broader therapeutic pipeline.

### Public Presence and Recognition
BioNTech has a strong digital presence with its official website at [https://biontech.de/](https://biontech.de/). It is also recognized globally for its role in pandemic response and has been featured in over 45 linked sources, including scientific journals, news outlets, and regulatory filings.

### Legal and Organizational Details
- **Aliases**: BioNTech is also known as Biopharmaceutical New Technologies, Biontech, BioNTech SE, BioNTech AG, BNT, BNTX, and BionTech.
- **Inception**: Officially founded in June 2008.
- **Situated in**: Germany, specifically in Mainz.

### Impact and Legacy
BioNTech’s development of the Pfizer–BioNTech COVID-19 vaccine not only saved millions of lives but also validated the potential of mRNA technology in modern medicine. This breakthrough has positioned BioNTech as a leader in biotechnology and mRNA research, with implications extending far beyond the pandemic into cancer therapy, rare diseases, and future pandemic preparedness.

## References

1. GRID Release 2017-05-22
2. [Source](https://www.lobbyfacts.eu/datacard/biontech-se?rid=516273537966-42)
3. [annual report](https://investors.biontech.de/node/7381/html)
4. [Source](https://www.nai-index.de/seiten/firmen_zusammensetzung.html)
5. [Source](https://www.nai-index.de/seiten/firmen_biontech.html)
6. Google Knowledge Graph
7. Bundestag Lobby Register
8. Czech National Authority Database
9. Aligned ISNI and Ringgold identifiers for institutions